Evidence map›Paper›PMID 40061103›Full record

ArticleEuropean heart journal. Case reports2025

Midostaurin-associated perimyocarditis: a case report of severe cardiotoxicity of novel targeted treatments for acute myeloid leukaemia and review of the literature.

Alev Kalkan, Lenhard Pennig, Roman Pfister, Oliver A Cornely, Jannik Stemler

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alev KalkanDepartment III of Internal Medicine, Heart Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.ORCID https://orcid.org/0009-0000-1418-0389
Lenhard PennigInstitute for Diagnostic and Interventional Radiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.ORCID https://orcid.org/0000-0002-6606-9313
Roman PfisterDepartment III of Internal Medicine, Heart Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.ORCID https://orcid.org/0000-0002-4358-5008
Oliver A CornelyDepartment I of Internal Medicine, ECMM Excellence Center for Medical Mycology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.ORCID https://orcid.org/0000-0001-9599-3137
Jannik StemlerDepartment I of Internal Medicine, ECMM Excellence Center for Medical Mycology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.ORCID https://orcid.org/0000-0001-9152-2469

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Midostaurin is a multikinase inhibitor for the treatment of Fms-like tyrosine 3 ( Case summary: A 24-year-old man with newly diagnosed AML and Discussion: In addition to the most frequently reported non-cardiac adverse effects of midostaurin, serious cardiotoxic complications appear to occur and may require discontinuation of therapy. This case highlights the importance of interdisciplinary work-up of a cardio-oncology pathway even in presumably low-risk patients and particularly in the context of rare cases of cardiotoxicity in novel cancer treatments.

Indexed as

Adverse effectsCardio-oncologyCardiotoxicityCase reportDrug–drug interactionsPerimyocarditisTherapeutic drug monitoring

Identifiers

PMID40061103
PMCPMC11886857

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.